Abstract
Ataxia telangiectasia-mutated and Rad3-related (ATR) protein kinase is an attractive anticancer target. In this study, comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) were performed on a series of aminopyrazine ATR inhibitors. The models generated by CoMFA had a cross-validated coefficient (q2) of 0.752 and a regression coefficient (r2) of 0.947. The CoMSIA models had a q2 of 0.728 and an r2 of 0.936. The reasonable quantitative structure-activity relationship model showed robust predictive ability. The contour map provided guidelines for building novel virtual compounds based on compound NO.40. In addition, the 3D structure of ATR was modeled by homology modeling. Molecular dynamic simulations were employed to optimize the structure. The docking results offered insights into the interactions between the inhibitors and the active site for potent analysis. This study provides useful guidance for the discovery of more potent compounds.
Keywords: ATR inhibitor, 3D-QSAR, CoMFA, CoMSIA, docking, homology modeling, molecular design.
Current Computer-Aided Drug Design
Title:3D-QSAR Analysis on ATR Protein Kinase Inhibitors Using CoMFA and CoMSIA
Volume: 10 Issue: 4
Author(s): Xiurong Li, Mao Shu, Yuanqiang Wang, Rui Yu, Shuang Yao and Zhihua Lin
Affiliation:
Keywords: ATR inhibitor, 3D-QSAR, CoMFA, CoMSIA, docking, homology modeling, molecular design.
Abstract: Ataxia telangiectasia-mutated and Rad3-related (ATR) protein kinase is an attractive anticancer target. In this study, comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) were performed on a series of aminopyrazine ATR inhibitors. The models generated by CoMFA had a cross-validated coefficient (q2) of 0.752 and a regression coefficient (r2) of 0.947. The CoMSIA models had a q2 of 0.728 and an r2 of 0.936. The reasonable quantitative structure-activity relationship model showed robust predictive ability. The contour map provided guidelines for building novel virtual compounds based on compound NO.40. In addition, the 3D structure of ATR was modeled by homology modeling. Molecular dynamic simulations were employed to optimize the structure. The docking results offered insights into the interactions between the inhibitors and the active site for potent analysis. This study provides useful guidance for the discovery of more potent compounds.
Export Options
About this article
Cite this article as:
Li Xiurong, Shu Mao, Wang Yuanqiang, Yu Rui, Yao Shuang and Lin Zhihua, 3D-QSAR Analysis on ATR Protein Kinase Inhibitors Using CoMFA and CoMSIA, Current Computer-Aided Drug Design 2014; 10 (4) . https://dx.doi.org/10.2174/1573409910666140701094853
DOI https://dx.doi.org/10.2174/1573409910666140701094853 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Atherogenic Role of Peroxisome Proliferator-Activated Receptor Ligands
Current Cardiology Reviews A QSAR Study on a Series of Indolin-2-Ones Acting as Non-Receptor Src Tyrosine Kinase Inhibitors
Letters in Drug Design & Discovery Triple Negative Breast Cancer: A Tale of Two Decades
Anti-Cancer Agents in Medicinal Chemistry Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies
Current Pharmaceutical Design Current Status of Clinical Trials for Small Cell Lung Cancer
Reviews on Recent Clinical Trials Targeting Inhibitor of Apoptosis Proteins (IAPs) for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Cabozantinib in Thyroid Cancer
Recent Patents on Anti-Cancer Drug Discovery Synergistic Effect of α-Solanine and Cisplatin Induces Apoptosis and Enhances Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer
Anti-Cancer Agents in Medicinal Chemistry Controversies in the Use of Nutritional Supplements in Ophthalmology
Current Pharmaceutical Design The Combination of the CIGB-300 Anticancer Peptide and Cisplatin Modulates Proteins Related to Cell Survival, DNA Repair and Metastasis in a Lung Cancer Cell Line Model
Current Proteomics Carrier Based Oral Nano Drug Delivery Framework: A Review
Current Nanomaterials HGF Airway Over-expression Leads to Enhanced Pulmonary Vascularization without Induction of VEGF
Current Angiogenesis (Discontinued) Stereocomplexation Assisted Assembly of Poly(γ-glutamic Acid)-graft-polylactide Nano-micelles and Their Efficacy as Anticancer Drug Carrier
Anti-Cancer Agents in Medicinal Chemistry Cellular Uptake of Neutral Phosphorodiamidate Morpholino Oligomers
Current Pharmaceutical Biotechnology Glucose-6-phosphate Dehydrogenase: a Biomarker and Potential Therapeutic Target for Cancer
Anti-Cancer Agents in Medicinal Chemistry Three Pt-Pt Complexes with Donor-acceptor Feature: Anticancer Activity, DNA Binding Studies and Molecular Docking Simulation
Anti-Cancer Agents in Medicinal Chemistry TNFR1 Regulates Ovarian Cancer Cell Tumorigenicity Through PIK3CB-p110Beta
Current Molecular Medicine Perspective on Nanoparticle Technology for Biomedical Use
Current Pharmaceutical Design Anticancer Properties of a New Hybrid Analog AD-013 Combining a Coumarin Scaffold with an α-methylene-δ-lactone Motif
Anti-Cancer Agents in Medicinal Chemistry